SPATA31C1

Across TCGA pan-cancer cohorts, SPATA31C1 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated SPATA31C1 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SPATA31C1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPATA31C1 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

OV, BRCA, and STAD are the cancer types where SPATA31C1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.844	<.001	48	view →
BRCA	OS	Median	All	0.725	0.964	<.001	23	view →
STAD	DFS	Median	III,IV	1.000	0.336	.038	10	view →
SCLC	DFS	Median	II,III,IV	0.137	0.562	.013	9	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
UCEC	DFS	Median	III,IV	1.000	0.543	.045	6	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →
SARC	DFS	Median	All	0.121	0.591	.042	3	view →
LIHC	DFS	Median	All	0.147	0.533	.007	3	view →
HNSC	DFS	Median	III,IV	1.000	0.294	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

SPATA31C1–OV (OS)

Open the OV breakdown →